Cardio-Metabolic

Testing new treatments in cardio-metabolic disease clinical trials is a challenge that requires the right investigators at the right sites. That is what we provide.

Patient recruitment and retention in this area is notoriously difficult. Julius Clinical has the leading scientific experts, experienced local investigators, and fine-tuned screening procedures to minimize this obstacle and provide the patient enrolment and retention your trial requires.

Meet our scientific leaders for cardio-metabolic trials

Rick Grobbee
Chief Scientific Officer

Diederick E. (Rick) Grobbee is Chief Scientific Officer at Julius Clinical and a professor of clinical epidemiology at the University Medical Centre (UMC) Utrecht, the Netherlands. His other current roles include chair of the circulatory health area at UMC Utrecht.

Meet our scientific leaders for cardio-metabolic trials

We collaborate with Prof. dr. Christophe Moreno, M.D., who is an expert in gastroenterology and hepatology and clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium. He is a valuable consultant to our NASH Clinical team.

Highlighted trials

Our Scientific Networks

NASH Clinical

NASH Clinical is our global network of experienced clinicians and investigators with a special interest and deep experience in NASH. The network is composed of endocrinologists, gastroenterologists, diabetologists, and internists.

Read more

Cardio Clinical

Cardio Clinical is a large global network of cardiologists and researchers who focus on developing novel therapies for cardiovascular diseases. Cardio Clinical comprises 1.000+ hospitals in 32 countries, providing sites and expertise around the world. The network has been involved in various large-scale randomised intervention trials on the prevention and treatment of cardiovascular disease.

Read more

Some highligted studies

Phase III, Global

Spire

1505 Patients | 27 Countries | 485 Sites

Reducing occurrence of major cardiovascular events in high risk subjects.

Phase III, Global

Ongoing

560 Patients | 12 Countries | 188 Sites

Cardiovascular events in patients who are statin intolerant.

Phase III, Global

Alecardio

4072 Patients | 19 Countries | 436 Sites

Treatment on Cardiovascular Mortality a Morbidity in Subjects with type 2 Diabetes who experienced a recent Acute Coronary Syndrome.


Our expert cardio-metabolic team

We have an expert cardio-metabolic operational team with many years of focused experience. They are skilled at providing highly efficient, end-to-end CRO services that streamline cardio-metabolic studies and fulfil the expectations one should have for an academic CRO.

Martin czakon
Rick grobbee
Manuel castro cabezas
Marco alings
Wiebe-Buitenwerf
Marcel bootsma
Elizabeth liano callahan
Vivian de jong

Related webinars

NAFLD: patient identification strategies

In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Public health and policy responses to NAFLD/NASH

Topics that has been discussed: The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Cardio-metabolic resources

Explore our cardio-metabolic capabilities, studies, and other resources.

Download

"*" indicates required fields

*

Request for proposal

"*" indicates required fields

*
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn